Aortic & peripheral vascular disease
Effects of resveratrol on aortic growth in patients with Marfan syndrome: a single-arm open-label multicentre trial
Authors' conclusion
Resveratrol treatment for 1 year may stabilise the aortic growth rate in adult patients with MFS.
Study context
- Population
- Adults aged 18–50 years with Marfan syndrome57 in final analysis
- Participants
- 61 adults
- Comparison
- Aortic growth rate before vs after initiation of resveratrol
- Outcome
- Change in estimated annual aortic growth at five predefined levels in the thoracic aorta (cardiac MRI, linear mixed model)
- Follow-up
- After 1 year of resveratrol treatment
Methodological detailsinvestigator-initiated
- Investigator-initiated
Main finding
As reported in the abstract
Estimated aortic growth rate (mm/year), before vs after treatment · 1.2±0.3 years
- Aortic root: from 0.39±0.06 to −0.13±0.23 mm/year (trend towards decrease)
- p=0.072
- Ascending aorta: from 0.40±0.05 to −0.01±0.18 mm/year (trend towards decrease)
- p=0.072
- Distal descending aorta: from 0.32±0.04 to 0.01±0.14 mm/year (trend towards decrease)
- p=0.072
Original publication
Effects of resveratrol on aortic growth in patients with Marfan syndrome: a single-arm open-label multicentre trial. Heart. Published 24 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →